Bloom Burton Has Negative Outlook of TSE:MBX FY2025 Earnings

Microbix Biosystems Inc. (TSE:MBX) – Analysts at Bloom Burton reduced their FY2025 earnings per share estimates for Microbix Biosystems in a report released on Wednesday, April 9th. Bloom Burton analyst D. Martin now expects that the company will post earnings per share of $0.01 for the year, down from their previous estimate of $0.03. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share.

Microbix Biosystems Price Performance

TSE MBX opened at C$0.36 on Monday. The company has a 50-day moving average price of C$0.43 and a 200-day moving average price of C$0.39. Microbix Biosystems has a 52 week low of C$0.29 and a 52 week high of C$0.55. The company has a quick ratio of 5.57, a current ratio of 7.15 and a debt-to-equity ratio of 22.61. The firm has a market capitalization of C$47.41 million, a P/E ratio of 13.71 and a beta of 0.34.

Insider Activity at Microbix Biosystems

In other Microbix Biosystems news, Director Bo Hollas sold 150,000 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of C$0.49, for a total value of C$73,500.00. Also, Director Cameron Lionel Groome sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of C$0.43, for a total value of C$86,500.00. Over the last ninety days, insiders sold 476,750 shares of company stock worth $213,995. 14.00% of the stock is owned by company insiders.

About Microbix Biosystems

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.